Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

ASP5736

Add links
From Wikipedia, the free encyclopedia

ASP5736
Identifiers
  • N-(diaminomethylidene)-1-(2,6-difluorophenyl)-4-fluoroisoquinoline-7-carboxamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC17H11F3N4O
Molar mass344.297 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C(=C1)F)C2=NC=C(C3=C2C=C(C=C3)C(=O)N=C(N)N)F)F
  • InChI=1S/C17H11F3N4O/c18-11-2-1-3-12(19)14(11)15-10-6-8(16(25)24-17(21)22)4-5-9(10)13(20)7-23-15/h1-7H,(H4,21,22,24,25)
  • Key:NPYWVXJXMOTDHT-UHFFFAOYSA-N

ASP5736 is an experimental drug developed by Astellas Pharma, which acts as a selective antagonist for the serotonin receptor 5-HT5A, with significantly higher potency than the older drug SB-699,551. In animal studies, it was found to reduce drug appropriate responding produced by LSD, but not DOI,[1][2] and has also been found to reduce the cognitive dysfunction and memory deficits produced by scopolamine in animal studies, which has been suggested may indicate a potential role for 5-HT5A antagonists in the treatment of schizophrenia, as well as other conditions such as fragile X syndrome.[3][4][5][6]

See also

[edit]

References

[edit]
  1. ↑ Popik P, Krawczyk M, Kuziak A, Bugno R, Hogendorf A, Staroń J, et al. (November 2019). "Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats". Journal of Psychopharmacology. 33 (11): 1447–1455. doi:10.1177/0269881119867603. PMID 31452444.
  2. ↑ Cyrano E, Popik P (February 2025). "Assessing the effects of 5-HT2A and 5-HT5A receptor antagonists on DOI-induced head-twitch response in male rats using marker-less deep learning algorithms". Pharmacological Reports. 77 (1): 135–144. doi:10.1007/s43440-024-00679-1. PMC 11743402. PMID 39602080.
  3. ↑ Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, et al. (October 2014). "ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia". European Neuropsychopharmacology. 24 (10): 1698–1708. doi:10.1016/j.euroneuro.2014.07.009. PMID 25108314.
  4. ↑ Yamazaki M, Okabe M, Yamamoto N, Yarimizu J, Harada K (March 2015). "Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats". Journal of Pharmacological Sciences. 127 (3): 362–369. doi:10.1016/j.jphs.2015.02.006. PMID 25837935.
  5. ↑ Yamazaki M, Yamamoto N, Yarimizu J, Okabe M, Moriyama A, Furutani M, et al. (May 2018). "Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia". European Neuropsychopharmacology. 28 (5): 620–629. doi:10.1016/j.euroneuro.2018.03.003. PMID 29571967.
  6. ↑ Yamazaki M, Arai T, Yarimizu J, Matsumoto M (September 2022). "5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an Fmr1-Targeted Transgenic Male Rat Model of Fragile X Syndrome". The International Journal of Neuropsychopharmacology. 25 (9): 786–793. doi:10.1093/ijnp/pyac041. PMC 9515134. PMID 35882205.
Retrieved from "https://en.wikipedia.org/w/index.php?title=ASP5736&oldid=1352443222"